Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

Stratification of Responders and Non-Responders in the Reach-1 Trial Based on Serum Proteomic Analysis

Sherry Owens, PhD, Michael A. Pratta, MSc, Hao Liu, PhD, Michael C. Arbushites, Chuan Tian, PhD, Michael D. Howell, PhD

Blood (2019) 134 (Supplement_1): 4531.

https://doi.org/10.1182/blood-2019-127147

Published: 2019

Journal Articles

A Biomarker Signature to Predict Complete Response to Itacitinib and Corticosteroids in Acute Graft Versus Host Disease

Michael A. Pratta, MSc, Hao Liu, PhD, Sherry Owens, PhD, Ying Yan, PhD, Michael C. Arbushites, Michael D. Howell, PhD

Blood (2019) 134 (Supplement_1): 3279.

https://doi.org/10.1182/blood-2019-124069

Published: 2019

Journal Articles

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Madan Jagasia, MD MS, Miguel-Angel Perales, MD, Mark A Schroeder, MD, Haris Ali, MD, Nirav N Shah, MD, Yi-Bin Chen, MD, Michael C. Arbushites, Fitzroy Dawkins, MD, Chuan Tian, PhD, Hanna Jean Khoury, MD FACP

Blood (2018) 132 (Supplement 1): 601.

https://doi.org/10.1182/blood-2018-99-116342

Published: 2018

Journal Articles

Plasma Biomarker Association with Response in Acute GVHD Subjects Treated with the Combination of Itacitinib and Corticosteroids in a Phase 1 Clinical Trial

Michael A. Pratta, MSc, Hao Liu, PhD, Michael C. Arbushites, Robert C Newton, PhD, Michael D. Howell, PhD

Blood (2018) 132 (Supplement 1): 4559.

https://doi.org/10.1182/blood-2018-99-116330

Published: 2018

NARROW

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Stratification of Responders and Non-Responders in the Reach-1 Trial Based on Serum Proteomic Analysis

A Biomarker Signature to Predict Complete Response to Itacitinib and Corticosteroids in Acute Graft Versus Host Disease

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Plasma Biomarker Association with Response in Acute GVHD Subjects Treated with the Combination of Itacitinib and Corticosteroids in a Phase 1 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Stratification of Responders and Non-Responders in the Reach-1 Trial Based on Serum Proteomic Analysis

A Biomarker Signature to Predict Complete Response to Itacitinib and Corticosteroids in Acute Graft Versus Host Disease

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Plasma Biomarker Association with Response in Acute GVHD Subjects Treated with the Combination of Itacitinib and Corticosteroids in a Phase 1 Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only